Skip to main content
    I

    Indaptus Therapeutics Inc (INDP)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.45
    +0.28 (+8.83%)

    Market Cap: $422.38M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Indaptus Therapeutics Inc (INDP) Financials: Revenue, Profit and Cash Flow

    Updated Nov 13, 2026. Financial statements from company filings, amounts in US dollars.

    Indaptus Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$20.85M, operating cash flow was -$14.82M and free cash flow was -$14.82M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$1.05M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $19.83M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Dec 2017N/AN/AN/AN/AN/A
    Dec 2016N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Cost of revenue$0$0$0$0$1.40K$852$854.00K$859.00K$829.00K$701.00K
    Gross profit$0$0$0$0-$1.40K-$852-$854.00K-$859.00K-$829.00K-$701.00K
    Research and development$9.34M$7.25M$7.62M$6.32M$2.52M$2.66M$26.66M$35.40M$24.30M$10.07M
    Operating income-$19.83M-$15.37M-$16.38M-$14.91M-$7.73M-$3.60M-$34.95M-$43.33M-$29.44M-$13.85M
    Net income-$20.85M-$15.02M-$15.42M-$14.32M-$7.71M-$3.58M-$47.60M-$43.54M-$28.91M-$13.36M
    EBITDAN/A-$15.37M-$15.42M-$14.32M-$7.71M-$3.60MN/A-$42.56M-$28.61M-$13.14M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.47K$0$0$0$1.93K
    Gross profit$0$0$0N/A$0$0$0$735$0$0$0$1.61K
    Operating income-$1.14M-$1.81M-$2.16M-$8.16M-$2.65M-$4.46M-$4.57M-$4.17M-$3.14M-$4.11M-$3.94M-$4.18M
    Net income-$1.05M-$1.79M-$2.54M-$8.11M-$2.98M-$5.23M-$4.53M-$4.13M-$3.07M-$4.02M-$3.81M-$4.00M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $8.51M were 91.4% of total assets of $9.31M, against total liabilities of $6.16M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$9.31M$7.34M$14.92M$28.06M$40.58M$1.78M$21.28M$61.51M$64.55M$24.72M
    Current assets$9.31M$6.62M$14.00M$27.24M$40.39M$1.73M$13.74M$43.56M$56.34M$20.67M
    Cash and equivalents$8.51M$5.79M$13.36M$9.63M$39.13M$1.64M$9.29M$39.25M$53.39M$16.44M
    Total liabilities$6.16M$3.39M$2.85M$3.43M$4.68M$2.02M$9.74M$7.96M$5.75M$2.02M
    Short-term debtN/A$84.16K$101.70K$80.49K$96.47K$96.47K$544.00KN/AN/AN/A
    Shareholder equity$3.15M$3.94M$12.08M$24.63M$35.90M-$237.70K$11.54M$53.55M$58.80M$22.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$31.21M$11.99M$2.18M$9.31M$6.84M$6.84M$5.41M$7.34M$8.24M$8.12M$10.95M$14.92M
    Total liabilities$20.88M$615.43K$933.00K$6.16M$2.23M$8.51M$2.61M$3.39M$2.24M$1.96M$1.59M$2.85M
    Cash and equivalents$26.60M$7.55M$1.50M$8.51M$5.83M$6.16M$3.89M$5.79M$7.38M$7.30M$9.74M$13.36M
    Shareholder equity$10.33M$11.37M$1.25M$3.15M$4.61M-$1.67M$2.80M$3.94M$6.00M$6.17M$9.36M$12.08M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$14.82M-$12.32M-$13.41M-$13.08M-$11.29M-$3.32M-$29.05M-$39.08M-$22.13M-$12.01M
    Capital expenditures$4$0$5$172.56K$3.85K$8.21M$921.00K$9.60M$5.00M$482.00K
    Free cash flow-$14.82M-$12.32M-$13.41M-$13.25M-$11.29M-$11.53M-$29.97M-$48.67M-$27.13M-$12.49M
    Share repurchases$569.47K$762.70K$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow$0$0$17.14M-$16.43M$447.75K$447.75K-$3.21M-$9.30M-$4.75M$4.72M
    Financing cash flow$17.54M$4.75M$0-$96.43K$48.34M$1.16M$2.37M$35.06M$63.71MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.44M-$1.93M-$7.01M-$3.19M-$2.57M-$4.02M-$5.05M-$3.40M-$2.51M-$2.48M-$3.94M-$2.60M
    Capital expendituresN/AN/A$3$0N/A$0$0N/A$0N/A$0N/A
    Free cash flowN/AN/A-$7.01M-$3.19MN/A-$4.02M-$5.05MN/A-$2.51MN/A-$3.94MN/A
    Last 12 quarters

    Frequently Asked Questions About INDP

    What is Indaptus Therapeutics' annual revenue?

    Indaptus Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Indaptus Therapeutics profitable?

    No. Indaptus Therapeutics reported net income of -$20.85M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does INDP generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$14.82M minus capital expenditures of $4 produced free cash flow of -$14.82M.

    How much debt does Indaptus Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $8.51M.